08/18/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 8/18/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the LumiraDx SARS-CoV-2 Antigen (Ag) Test. The LumiraDx SARS-CoV-2 Ag Test is authorized for use using nasal swab specimens collected from individuals who are suspected of COVID-19 by their healthcare provider within the first 12 days of the onset of symptoms. (PDF)
.png)
No hay comentarios:
Publicar un comentario